Over-correction avoided by administering correct dosage

Article

Over-correction in children with intermittent exotropia can be avoided by using the correct surgical dosage.

Over-correction in children with intermittent exotropia can be avoided by using the correct surgical dosage.

A team led by Dr Deborah Buck, Institute of Neuroscience, Medical School, Newcastle University, Newcastle upon Tyne, UK, included 87 children with intermittent exotropia who underwent surgery in 18 centres across the UK.

Primary outcome measures included motor/sensory outcome and the secondary outcome measure was satisfactory control assessed by the Newcastle Control Score (NCS).

Of the 87 children studied, 72 were available for review data. Preoperative and surgical characterisitics had no effect on the primary outcome and satisfactory control was achieved in 65% of patients, whilst 20% still had intermittent extropia.

It was discovered that 35%, 28% and 37% of patients had excellent, fair and poor primary outcomes, respectively. Persistent over-correction was found in 15% of the patients and there was no recorded relationship between over-correction and preoperative characteristics or surgical dose/type.

At near and distance visions the median angle improved by 12 prism dioptres (PD) and 19 PD, respectively. The median NCS improved by five and the 40% who were initiallt over-corrected remained over-corrected by the last postoperative assessment.

The abstract was published in the latest issue of the British Journal of Ophthalmology.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.